Aspect Biosystems and Novo Nordisk entered a collaboration and license agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions in the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity.   The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. The...